Roohi Mariam Peter has been a journalist at Labiotech since 2023. She writes news articles and in-depth features on healthcare, biopharma, science, fundraising, markets, and emerging therapies. She ...

New therapies in the clinic for bipolar disorder hope to meet unmet needs of efficacy and minimal side effects.

June 2026 saw drug development in oncology and neurology continue and biotech deals over small molecules and RNA therapies ...

Delve into the hidden innovation system of drug repurposing. When patents expire and commercial value fades, a new wave of ...

Parabilis Medicines, NewLimit, Enliven Therapeutics, and Kardigan bagged the biggest biotech funding rounds overall in June 2026.

Novartis’ current strategy can be traced back to October 2023, when the Swiss pharma completed the spin-off of Sandoz, its generics and biosimilars business. The company described the move as the ...

Long renowned for its rich history, striking architecture, and thriving technology sector, Prague – and Czechia as a whole – is increasingly gaining recognition for something else: a fast-growing life ...

What readers will learn: Reduce manual effort through one automated, closed T cell manufacturing workflow, transferred across multiple sites with reproducible outcomes. Strengthen QC readiness through ...

Artificial intelligence (AI) may be transforming drug discovery, but one of the industry’s biggest problems remains unchanged: much of the biology used to develop new medicines still does not fully ...

There was a time when the numbers told an unoptimistic story about Roche. Its three oncology blockbusters, Herceptin, Avastin, and Rituxan, had built it into the world’s largest cancer drug maker, ...

So far, the visible strategy around bronchiectasis has been managing the problems it creates — mucus retention, repeated infections, airway inflammation, and exacerbations. Airway clearance, ...